Federal Disclosure Reveals FBI Investigation Into Major Cannabis Operator
Washington, Friday, 14 August 2026.
Newly released FBI records show federal authorities investigated Curaleaf over undisclosed funding linked to a Russian oligarch, signaling intense scrutiny for state-licensed cannabis firms seeking federal Drug Enforcement Administration registration.
Federal Disclosure Reveals FBI Investigation Into Major Cannabis Operator
The Federal Bureau of Investigation has released 64 pages of internal records regarding major cannabis operator Curaleaf (CURLF), while withholding 147 pages under grand jury secrecy rules following a Freedom of Information Act request [1]. The records were provided to The Newsground by researcher Joe Lloyd, who filed the FOIA request for FBI materials mentioning Curaleaf [1]. Legal and industry experts warn that state-licensed operators seeking Drug Enforcement Administration registration now face intense federal scrutiny regarding their ownership structure, financing, compliance histories, and diversion controls [1]. This disclosure highlights growing compliance risks for multi-state cannabis executives and investors navigating the friction between federal enforcement and state-level legalization in August 2026 [1].
Historical Grand Jury Probes and Financial Scrutiny
Background reports indicate that two federal grand juries, one in Manhattan and one in Philadelphia, examined Curaleaf’s financial activities, though both proceedings concluded without bringing any criminal charges [1]. Federal investigators scrutinized specific areas of Curaleaf’s operations, including beneficial ownership, foreign financing, shareholder disclosure, capital sources, representations in state license applications, and fund movement through corporate entities [1]. On 2018-10-26, the U.S. Attorney’s Office in Manhattan issued a federal grand jury subpoena focused on Curaleaf, shortly before the company went public on the Canadian Securities Exchange with a $4 billion valuation [2]. FBI investigators questioned individuals regarding Curaleaf’s Pennsylvania licensing submissions, specifically probing whether shareholder and financing information was accurately disclosed, including potential omissions of Roman Abramovich [1].
Industry Reaction to Federal Scrutiny
On August 13, 2026, MMJ International Holdings, Inc. highlighted that the FBI records demonstrate the high level of federal scrutiny state-licensed marijuana operators may face when seeking Drug Enforcement Administration (DEA) registration [1]. Duane Boise, CEO of MMJ International Holdings, stated that state licensing was never designed to substitute for federal due diligence [1]. Boise noted that the moment a state marijuana operator applies for DEA registration, its history, ownership, financing, disclosures and compliance systems can become federal questions [1]. MMJ International Holdings is a petitioner in litigation regarding the April 2026 federal marijuana rescheduling order and has spent over eight years pursuing federal pharmaceutical pathways for cannabinoid medicines [1].
Curaleaf Response and Compliance Risks
Curaleaf explicitly denied knowledge of being a subject of an FBI investigation, stated it complies with all ownership-disclosure requirements, and asserted that Roman Abramovich does not hold, to their knowledge, direct or indirect shares in the company [1]. The company issued a statement claiming it was never notified that it was a subject with respect to any FBI investigation [1]. Despite this, the reported investigation highlights the intensive federal scrutiny state-licensed marijuana operators will face when seeking DEA registration [1]. Companies asking for the benefits of federal recognition should expect federal authorities to examine who owns them, who financed them, how they operated and whether their representations were complete and accurate [1].